1.210DKK+1.68%Mkt Cap: 599.07M DKKP/E: —Last update: 2026-05-13
BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and …
Industry Peers
Diagnostics & Researchloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-17.29
PEG—
P/B9.53
P/S14.87
EV/EBITDA-7.11
EV/Revenue13.69
EPS (TTM)-0.15
EPS (Forward)-0.07
Cash Flow & Leverage
FCF Yield-7.68%
FCF Margin-114.23%
Operating CF-77.07M DKK
CapEx (TTM)—
Net Debt/EBITDA0.61
Net Debt-47.37M DKK
Technical
SMA 500.9844 (+22.9%)
SMA 2001.105 (+9.5%)
Beta1.28
S&P 52W Chg24.23%
Avg Vol (30d)604.09K
Avg Vol (10d)462.98K
Technical Indicators
RSI (14)64.5
MACD0.0692
MACD Signal0.0609
MACD Hist.+0.0083
BB Upper1.307 DKK
BB Middle1.078 DKK
BB Lower0.8494 DKK
BB Width42.42%
ATR (14)0.0591 DKK
Vol Ratio (20d)1.58x
52W Range
0.839049% of range1.600
52W High1.600 DKK
52W Low0.8390 DKK
Profitability
Gross Margin75.44%
EBITDA Margin-192.72%
Profit Margin-203.83%
Oper. Margin-107.49%
ROE-130.33%
ROA-88.13%
Revenue Growth47.20%
Earnings Growth—
Balance Sheet
Debt/Equity0.12
Current Ratio3.25
Quick Ratio2.81
Book Value/Sh0.1270 DKK
Cash/Share0.1110 DKK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 DKK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.495.10M
Float458.86M
Insiders29.80%
Institutions6.21%
Analyst Consensus
Rating—
Target (Mean)1.750 DKK
Target Range1.750 DKK – 1.750 DKK
# Analysts1
Company
Market Cap599.07M DKK
Enterprise Value551.71M DKK
Revenue (TTM)40.29M DKK
Gross Profit30.39M DKK
Net Income (TTM)-82.12M DKK
Revenue/Share0.0750 DKK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees46
Last Price1.210 DKK
CountryDK
SectorHealthcare
IndustryDiagnostics & Research
ISIN—